Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks
Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 [Yahoo! Finance]
Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
?Emergent BioSolutions (EBS) Receives a New Order from US Department of War [Yahoo! Finance]
New York Sues Former C.E.O. of Covid Vaccine Maker Over Insider Trading [The New York Times]